On February 22, 2024, the board of directors of Zymeworks Inc., upon recommendation from the nominating and corporate governance committee of the Board, appointed Mr. Scott Platshon, Partner of EcoR1, as a director of the Company, effective as of February 22, 2024. Mr. Platshon was appointed as a Class III director with a term expiring at the Company?s 2024 annual general meeting of stockholders. Mr. Platshon will not be named to any committees of the Board in connection with his appointment.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.39 USD | -1.53% | -8.40% | -19.68% |
06-17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
06-17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.68% | 607M | |
+14.73% | 121B | |
+17.19% | 112B | |
+3.20% | 22.57B | |
-18.45% | 20.82B | |
-15.40% | 16.3B | |
-16.87% | 16.19B | |
-42.36% | 16.17B | |
+1.02% | 13.17B | |
+22.94% | 11.11B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Appoints Scott Platshon as Director